Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers investor.lilly.com
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy investor.lilly.com
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity investor.lilly.com
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience investor.lilly.com
Lilly confirms date and conference call for first-quarter 2025 financial results announcement investor.lilly.com
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial investor.lilly.com
